Skip to main content
  • COVID-19 Vaccination Post-ACS Did Not Significantly Reduce MACE: Trial Analysis

    A secondary analysis shows that patients with at least one COVID-19 vaccine after experiencing an acute coronary syndrome (ACS) had similar rates of major adverse cardiovascular events (MACE) to unvaccinated patients.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details